Letrozole is an oral ovulation-induction medication: one 2.5 mg tablet once daily for five days at the start of the cycle. It blocks the enzyme aromatase, the resulting estrogen dip prompts the pituitary to release more follicle-stimulating hormone (FSH), which matures and releases an egg.
The evidence is unusually strong: in the PPCOS II trial, women with polycystic ovary syndrome (PCOS) on letrozole had a 27.5% cumulative live birth rate over five cycles versus 19.1% on clomiphene — a 44% relative improvement — Legro et al., 2014 — and a 2023 meta-analysis of 29 randomized trials confirmed the pattern; letrozole is now the first-line oral drug for ovulation induction in PCOS.
It is not automatically better for every diagnosis — in unexplained infertility, one large US trial found letrozole slightly less effective per cycle than clomiphene. This guide covers where it wins, dosing, costs and birth-defect data.
How this article was researched: the ProIVF Medical Editorial Team reviewed the FDA Femara (letrozole) label with randomized trials, meta-analyses and registry cohorts; the Medical Advisory Board checked the draft; every figure links to its source.
What Is Letrozole and How Does It Work?
Letrozole is an aromatase inhibitor, labeled as a breast cancer drug (brand name Femara). Ovulation induction with it is off-label: common and guideline-supported, but not an FDA-approved fertility indication — DailyMed label.
How Does Lowering Estrogen Grow a Follicle?
Aromatase converts androgens into estrogens; letrozole shuts it down in the ovary, fat tissue and brain, so the pituitary releases more FSH, removing the negative-feedback brake the follicle’s own estradiol applies.
Working through your own pituitary rather than as an injected hormone, it produces one, occasionally two, dominant follicles per cycle — not the eight or ten of gonadotropins — Aydın et al., 2026.
Unlike clomiphene, which blocks estrogen receptors and can thin the lining and thicken cervical mucus, letrozole has no anti-estrogenic effect on the endometrium — the lining keeps developing while the follicle grows.
What Does the FDA Label Say in Numbers?
| Property | What the label says |
|---|---|
| How taken | Orally, without regard to meals |
| Elimination half-life | About 2 days |
| Steady state (2.5 mg daily) | 2–6 weeks |
| Metabolism | CYP3A4 and CYP2A6 |
| Excretion | 90% recovered in urine |
| Contraindicated in | Pregnancy — fetal harm |
Two label details matter: slow clearance leaves measurable drug for days after a course — hence the pregnancy test before each new cycle — and tamoxifen 20 mg daily reduced letrozole plasma levels by an average 38%, so mention past tamoxifen use.
Letrozole vs Clomiphene Citrate: What Does the Evidence Show?
Letrozole displaced clomiphene citrate (Clomid, Serophene) — first-line for five decades — in PCOS on randomized data. A ratio of 1.0 means no difference.
| Outcome (letrozole vs clomiphene) | Result | Source |
|---|---|---|
| Cumulative live birth, 5 cycles (PCOS) | 27.5% vs 19.1% (rate ratio 1.44, 95% CI 1.10–1.87) | PPCOS II 2014 |
| Cumulative ovulation rate (PCOS) | 61.7% vs 48.3% of cycles | PPCOS II 2014 |
| Live birth (meta-analysis, 29 RCTs / 3,952 women) | RR 1.49 (1.27–1.74) | Liu et al. 2023 |
| Clinical pregnancy | RR 1.48 (1.34–1.63) | Liu 2023 |
| Ovulation | RR 1.14 (1.06–1.21) | Liu 2023 |
| Live birth (IPD meta-analysis, 20 RCTs / 3,962 women) | RR 1.43 (1.17–1.75) | Wang et al. 2019 |
| Time to pregnancy | Hazard ratio 1.72 (1.38–2.15) | Wang 2019 |
| Multiple pregnancy | RR 0.42 (0.18–0.98) — lower | Miller & Pinheiro 2026 |
| Miscarriage | RR 0.97 (0.73–1.28) — no difference | Miller & Pinheiro 2026 |
| Live birth per cycle, unexplained infertility | 18.7% letrozole, 23.3% clomiphene, 32.2% gonadotropin | AMIGOS 2015 |
The Trial That Changed Practice
PPCOS II randomized 750 women with PCOS to letrozole or clomiphene for up to five double-blind cycles: 103 of 374 delivered versus 72 of 376 (P=0.007); ovulation in 834 of 1,352 versus 688 of 1,425 cycles (P<0.001) — Legro et al., 2014.
“As compared with clomiphene, letrozole was associated with higher live-birth and ovulation rates among infertile women with the polycystic ovary syndrome.” — Legro RS et al., N Engl J Med 2014;371(2):119–129, PubMed 25006718
Pregnancy loss (31.8% vs 29.1%), anomalies (four vs one, P=0.65) and side effects were similar between arms; clomiphene’s hot flashes, mood swings and visual disturbances often stop treatment.
Letrozole’s advantage grew with baseline testosterone in the IPD meta-analysis (interaction RR 1.29, 95% CI 1.01–1.65; Wang 2019), and the 2026 update across 32 trials confirmed the multiple-pregnancy advantage (Miller & Pinheiro 2026).
Where Letrozole Does Not Win: Unexplained Infertility
The AMIGOS trial randomized 900 ovulatory women with unexplained infertility to gonadotropin, clomiphene or letrozole for up to four cycles; live birth per cycle: 32.2%, 23.3% and 18.7% — Diamond et al., 2015. Letrozole was significantly below standard therapy (gonadotropin or clomiphene; P=0.003) and gonadotropin alone (P<0.001), though not clomiphene alone (P=0.10).
In other words: the letrozole advantage is specific to PCOS. If your diagnosis is unexplained infertility, trial data do not support letrozole “because it’s the modern choice”; ASRM frames oral agents or gonadotropins with intrauterine insemination (IUI) before in vitro fertilization (IVF), typically over 3 or 4 cycles — ASRM Practice Committee, 2020.
Does Letrozole Protect the Uterine Lining?
Yes — a receptive endometrial pattern in 77.5% of letrozole cycles versus significantly fewer on clomiphene, with higher volume and blood-flow indices — Wang et al. 2019.
In a randomized study of 160 women with PCOS (letrozole 2.5 mg vs clomiphene 50 mg), clinical pregnancy reached 30.0% versus 13.8% and ongoing pregnancy 22.5% versus 10.0% — why clinics switch patients to letrozole after a thin lining; our IUI procedure guide walks a full cycle.
Who Should Take Letrozole — and Who Should Not?
Which Diagnoses Favor Letrozole?
PCOS is letrozole’s home ground — roughly 80% of women with anovulatory infertility have PCOS — Balen et al., 2016, the group where letrozole beat clomiphene in every major trial; guidance now positions it first-line; our PCOS and IVF guide covers the wider pathway.
Clomiphene resistance (no ovulation at escalating doses) or intolerance (hot flashes, mood changes, blurred vision, thin lining) also points to letrozole: a 2026 randomized comparison of 216 IUI women put letrozole ahead on pregnancy, live birth, receptivity and multifetal rates — Am J Transl Res 2026.
In unexplained infertility letrozole is a reasonable low-risk option — not the superior choice; expect a 3–4-cycle course with IUI before escalating (see alternatives to IVF and IUI vs IVF).
How Is Letrozole Used in IVF Cycles?
Three uses are well documented:
- Mild (“mini”) stimulation — letrozole plus low-dose injectable FSH instead of high-dose gonadotropins.
- Endometrial preparation for frozen transfer — lower hypertensive risk than artificial cycles.
- Protocol layering — combined with injectables.
In 125 non-obese women with PCOS, a letrozole protocol needed fewer gonadotropin units for the same oocyte yield (median 6 total, 5 mature) and more fresh transfers, 80% vs 60% — D’Amato et al. 2018. In 2,427 women with PCOS, letrozole-stimulated frozen transfers carried lower hypertensive-disorder risk: adjusted odds ratio 0.63 (95% CI 0.40–0.98) in singletons, 0.52 (0.30–0.87) in twins — Zhang et al. 2021. See the mini IVF guide and IVF stimulation protocols guide.
When Must Letrozole Be Avoided?
Letrozole is contraindicated in pregnancy and can cause fetal harm — stop once a pregnancy is confirmed and test after any missed period before the next dose; the label also recommends 2.5 mg every other day in severe hepatic impairment.
Pre-existing liver disease, unexplained uterine bleeding and suspected estrogen-dependent tumour warrant a specialist conversation first; letrozole has no role in male factor infertility.
How Is Letrozole Dosed, and When in the Cycle?
What Is the Standard Protocol?
2.5 mg or 5 mg once daily for five consecutive days, starting on cycle day 3, 4 or 5 (day 1 = first full bleeding day) — the PPCOS II schedule used by most clinics; ovulation typically follows 5–10 days after the last tablet.
| Protocol | Dose and timing | Used for |
|---|---|---|
| Standard | 2.5–5 mg daily × 5 days, cycle days 3–7 | First-line PCOS induction |
| Higher-start | 5 mg daily × 5 days | Non-response to 2.5 mg |
| Extended (10-day) | 2.5 mg daily × 10 days | Thin 5-day response |
| Stepwise | 5 mg × 5 days, extended 2–5 days, then 7.5 mg | Resistant PCOS |
What If I Don’t Respond?
Two dose strategies have randomized data:
- 10-day course: in 80 randomized women with PCOS, 2.5 mg daily for 10 days produced follicular response in 85.0% of first cycles versus 52.5% on five days (P=0.002), no ovarian hyperstimulation syndrome — J Hum Reprod Sci 2026.
- Stepwise escalation: in 313 resistant anovulatory PCOS women undergoing IUI (5 mg × 5 days, extended 2–5 days, then 7.5 mg for 2–5 days), ten-week clinical pregnancy rates were 18.72%, 14.45% and 11.76% — no difference — with multiple pregnancies only in the standard-dose group — Clin Exp Reprod Med 2026.
Extending the window is well tolerated, but set a limit with your clinician as resistance grows.
What Does Monitoring Involve — and How Many Cycles?
Most clinics do one or two transvaginal ultrasounds per cycle, often add a mid-cycle progesterone or luteinizing hormone (LH) test, and trigger with human chorionic gonadotropin (hCG) before timed intercourse or IUI; unmonitored cycles are cheaper but never confirm ovulation.
Two benchmarks: ASRM frames 3 or 4 cycles of oral stimulation with IUI for unexplained infertility, and many clinicians allow up to six ovulatory cycles in PCOS before gonadotropins, laparoscopic drilling or IVF. If ovulation comes but no pregnancy after six good cycles, another drug is unlikely to be the answer — agree the escalation rule in advance.
What Success Rates Can You Expect?
Two framing points: cumulative live birth over five cycles is not five times the per-cycle rate (early conceivers stop contributing cycles), and ovulation and live birth rates use different denominators — one trial can post roughly 62% ovulation and 27.5% live birth — ask for both. To compare oral induction with IVF routes, our IVF success rate guide scales each option by age.
What Are the Side Effects and Birth Defect Risks?
What Side Effects Are Common?
At ovulation-induction doses (2.5–5 mg for five days) letrozole is generally well tolerated; PPCOS II found adverse events similar between the two drugs (Legro 2014). Most reported:
- Hot flashes and night sweats (most characteristic)
- Headache, dizziness and fatigue
- Nausea, breast tenderness, mood changes and irritability
- Joint or muscle aches (more prominent at breast-cancer doses)
Because letrozole lowers estrogen rather than blocking receptors, many women who found clomiphene intolerable tolerate it better. Ovarian hyperstimulation syndrome (OHSS) is rare with letrozole alone, a consequence of the one-to-two-follicle response; the 10-day study reported zero cases.
Does Letrozole Cause Birth Defects?
A 2005 abstract suggesting excess anomalies circulated widely; peer-reviewed data point the other way:
- 911 newborns, five Canadian centres: malformations and chromosomal abnormalities 2.4% letrozole-conceived (14/514) vs 4.8% clomiphene-conceived (19/397); major malformations 1.2% vs 3.0%; cardiac anomalies more frequent with clomiphene (1.8% vs 0.2%, P=0.02) — Tulandi et al. 2006.
- Japanese national ART registry, 3,136 natural vs 792 letrozole-induced cycles with single-embryo transfer: major anomalies 1.9% vs 1.5% (adjusted OR 1.24, 95% CI 0.64–2.40, P=0.52), no organ-system increase, and a lower miscarriage risk (adjusted OR 0.37, 95% CI 0.30–0.47) — Tatsumi et al. 2017.
- Systematic review, 20 studies / 6,679 patients: no increased malformation or loss risk across timed intercourse, IUI or frozen transfer — but certainty is very low — Etrusco et al. 2025.
“Reassuring but not proven” — the accurate summary.
Does Letrozole Raise the Twin Risk?
The mono-follicular response pays off: in AMIGOS, multiple gestation occurred in 13% of letrozole, 9% of clomiphene and 32% of gonadotropin pregnancies; every letrozole or clomiphene multiple was a twin, versus 24 twin and 10 triplet gestations on gonadotropin (Diamond 2015), and the 2026 meta-analysis confirmed the lower rate (Miller & Pinheiro 2026).
How Much Does Letrozole Cost?
The drug is a generic tablet; the real cost is monitoring:
| Item | Typical cost (US) |
|---|---|
| Letrozole (generic, 5-day course) | $10–$50 |
| Monitoring (1–2 ultrasound scans) | $150–$400 |
| Trigger injection | $50–$150 |
| Total (medication + monitoring) | $50–$500 |
That $50–$500 per cycle total matches our alternatives to IVF guide — roughly one-tenth of a gonadotropin cycle and a fraction of IVF. Adding injectable FSH raises the medication bill to hundreds or low thousands; see mini IVF and IVF medications. The tablet costs about the same worldwide, so quote differences are monitoring fees — ask for both lines separately.
Patient Stories: Three Different Journeys to Ovulation
Shared with consent; names and identifying details changed.
Ana, 29 — Manila, Philippines. PCOS; three monitored cycles, one baby. Her first 2.5 mg cycle produced no follicle; two 5 mg cycles ovulated but tested negative. On the third 5 mg cycle a 19 mm follicle appeared on day 12, she triggered with hCG, positive test eleven days later — medication roughly $90 per cycle, monitoring $130. “Ovulating is not the same as getting pregnant. My doctor said give it three good cycles, and she was right.”
Sarah, 34 — Toronto, Canada. Unexplained infertility; letrozole plus IUI, then IVF. Regular cycles, normal hormones, open tubes. Three monitored cycles — about $60 a month in medication, roughly $650 per IUI — all negative. Her clinic showed her the AMIGOS data rather than escalating; after the recommended 3–4 cycles she moved to IVF, euploid transfer nine months later. “I don’t resent those three cycles… But I’m glad we didn’t do six.”
Wei, 36 — Chengdu, China. Clomiphene intolerance; pregnant on the third letrozole cycle. She ovulated on clomiphene but with severe hot flashes and a lining of only 6.1 mm on trigger day. On letrozole 5 mg it reached 8.4 mm on the same cycle days, the flashes stopped, and she delivered at 39 weeks. “Nobody told me there were two different oral drugs — I spent four months thinking I was just bad at tolerating medicine.”
FAQ
Q: How long does letrozole take to work?
Ovulation usually follows 5–10 days after the last tablet of the five-day course, and slow clearance means the drug is gone within about a week (see the FDA label table).
Q: What is the highest dose of letrozole for fertility?
The standard maximum is 5 mg daily for five days (the PPCOS II dose); stepwise protocols escalate to 7.5 mg for non-responders. Of 313 resistant women, 219 responded to standard dosing, 83 to extended 5 mg and 11 to extended 7.5 mg (Clin Exp Reprod Med 2026); above 7.5 mg there is no randomized fertility data; continuous 2.5 mg is the breast-cancer regimen.
Q: When is the best time to take letrozole — morning or night?
Any hour works — the tablet is taken without regard to meals, with no timing preference; the cycle day matters more: start on day 3–5. Clinics often suggest evenings, at a fixed time, to sleep through any headache.
Q: Are there foods to avoid while taking letrozole?
The label lists no food restrictions at induction doses (2.5–5 mg); precautions: letrozole is metabolized by CYP3A4 and CYP2A6, and cancer literature flags grapefruit and St John’s wort as shifting aromatase-inhibitor levels — interaction review, 2023 — never measured at fertility doses; tell your clinic about every medication and supplement rather than self-adjusting.
Q: Is letrozole safe — does it cause birth defects?
No dataset has shown increased risk; the two largest cohorts favor at-least-equal safety versus clomiphene (full numbers above, with the 2025 review’s “very low” certainty). Letrozole stays contraindicated in pregnancy: stop before conception and test before each new cycle.
Q: Is letrozole the same as Femara?
Yes — Femara is letrozole’s brand name, and the 2.5 mg tablets are equivalent. A generic five-day course costs $10–$50, the brand many times more; Femara’s approved indication is breast cancer, so every fertility use is off-label.
Q: Can I take letrozole if I have PCOS and a high BMI?
Yes — letrozole is used across body mass index (BMI) categories, though metabolic profile modifies response (testosterone interaction above); ask whether to add metformin, start at 5 mg, and how to monitor; see the PCOS and IVF guide.
How to Plan Your Next Step
Letrozole is one of the few cheap, evidence-backed steps in fertility treatment — but it has an indication, not a universal first move. Three things before cycle one:
- Confirm the diagnosis that makes letrozole the right drug — PCOS anovulation is where the evidence is strongest; unexplained infertility is where it is weakest.
- Agree the dose ladder and exit point in writing — standard, extended and stepwise dosing plus a fixed cycle limit.
- Get medication and monitoring quoted as separate lines — the tablet is cheap everywhere; monitoring fees vary between destinations.
To choose where to run a monitored cycle, browse hospital profiles for success rates, pricing and reviews, or contact our team to match your diagnosis to a clinic; our IUI procedure guide and alternatives to IVF guide cover the rest.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Letrozole is a prescription medicine; ovulation-induction use is off-label and must be supervised by a licensed reproductive specialist. Cited success rates and side-effect frequencies are population-level data, not individual predictions. Never start, stop or adjust a fertility medication without your own clinical team.
This article was written by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board, drawing on the sources linked throughout.
Last updated: September 11, 2026
